This is the authors' abstract. We don't add key points for this paper.
Circulating tumour DNA (ctDNA) is a valuable biomarker for relapse monitoring. However, current personalized approaches are unable to detect emerging clones, and perioperative ctDNA dynamics remain to be defined. We prospectively validated Hi-SECURE, a tumour-informed MRD assay, in 132 NSCLC patients (POEM cohort). Analytical performance was benchmarked against reference standards and a fixed 158-gene panel. A perioperative blood (PB) staging system was proposed and externally validated. Hi-SECURE achieves a limit of detection of 0.005% with a DNA input of 20 ng. At the landmark time point, ctDNA positivity predicted recurrence with a hazard ratio (HR) of 17.14 (95% CI: 3.06–96.11). Hi‑SECURE outperformed the fixed panel, especially in stage IA (25.0% vs 6.8% detection rate, p = 0.020). Pre‑ and postoperative ctDNA status enabled PB staging, which showed strong prognostic discrimination (log rank p < 0.001), was validated across external cohorts. Moreover, Hi-SECURE’s core panel identified drug-resistant mutations (e.g., EGFR -T790M) during follow-up, enabling timely therapeutic adjustments. In conclusion, Hi‑SECURE is a highly sensitive and specific personalized MRD assay. The proposed PB staging system provides a functional, dynamic complement to anatomical TNM staging, enabling precise prognostic stratification and offering potential guidance for adjuvant therapy, resistance monitoring, and immunotherapy candidate selection.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: